BIOCON TO COLLABORATE WITH BAYER ON INSUGEN IN CHINA

India-based Biocon has entered into a licensing agreement with Bayer for the exclusive marketing and trademark rights for Insugen in the Chinese market. The collaboration may also be expanded to other countries in Asia Pacific. After completion of necessary local registration trials, Insugen, a recombinant human insulin, is expected to be launched in China within two to three years.

The exclusive marketing rights and trademark agreement covers three formulations of insulin: fast-acting, intermediate-acting and mixed-acting, in both vials and cartridges. These apply to both Type 1 and Type 2 diabetes.

Currently, 40 million people in China suffer from diabetes, and there are an estimated 3,000 new cases each day.